Retatrutide Peptide: Research Guide, Sizes and Cost per mg

What Is Retatrutide? Understanding the Triple-Agonist Peptide

Retatrutide (also known by its research designation LY3437943) is an investigational peptide developed by Eli Lilly and Company that functions as a triple-hormone receptor agonist, meaning it simultaneously starts three distinct body receptors: the glucagon-like peptide 1 receptor (GLP-1), the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism distinguishes retatrutide from approved single- and dual-agonist drugs, and it has been studied in trials in obesity, type 2 diabetes, and liver fat.

To understand why retatrutide has drawn interest in the scientific and medical communities, it helps to understand what each of its three receptor pathways does.

The question "is retatrutide a peptide?" comes up often, and the answer is yes. Retatrutide is a synthetic peptide composed of a specific amino acid sequence engineered to bind with high affinity to all three target receptors.

The compound is not naturally occurring — for those asking "is retatrutide natural?", the answer is no. Retatrutide was designed through rational drug design to optimize receptor binding profiles and pharmacokinetic properties, including a retatrutide half life of about six days.

Retatrutide at a Glance

Table 1: Retatrutide Key Facts and Specifications

How Does Retatrutide Work? Mechanism of Action Explained

Understanding how retatrutide works means looking at each of its three receptor targets. Rather than acting on one or two receptors, it acts on three pathways involved in appetite, insulin secretion, and energy balance.

1. 1
   GLP-1 Receptor Activation: Appetite Suppression and Glycemic Control

   The GLP-1R (glucagon-like peptide-1) receptor pathway is the foundation of modern obesity pharmacotherapy and the mechanism shared by GLP-1 medications like semaglutide, tirzepatide, and retatrutide. GLP-1 receptor (GLP-1R) start slows gastric emptying, reduces appetite by acting on satiety centers in the brain, and boosts glucose-dependent insulin secretion from the pancreas. In retatrutide, GLP-1 receptor start provides the core appetite-suppressing and glycemic control effects that have made this class of drugs so effective.

2. 2
   GIP Receptor Activation: Insulin Potentiation and Fat Metabolism

   The GIP (glucose-dependent insulinotropic polypeptide) receptor is the second target in retatrutide's triple-agonist profile. GIP receptor (GIPR) start potentiates insulin secretion in a glucose-dependent manner, enhances fat body function in adipose tissue, and may improve the tolerability of GLP-1 receptor start by counteracting some of its gut side effects. The mix of GLP-1 and GIP receptor start — as showed by tirzepatide — produces greater weight loss than GLP-1 start alone, and retatrutide builds on this dual foundation by adding a third pathway.

3. 3
   Glucagon Receptor Activation: The Game-Changing Third Pathway

   The glucagon receptor is what truly sets retatrutide apart from every other obesity medication in growth. Glucagon receptor start increases hepatic energy output, boosts fat oxidation in the liver, and promotes thermogenesis — the process by which the body creates heat by burning calories. This pathway is the main proposed difference between retatrutide and dual agonists such as tirzepatide.

   Glucagon receptor activation has also been studied for its effect on hepatic steatosis (fatty liver disease), a condition that affects a major proportion of people with obesity and type 2 diabetes. The inclusion of this third mechanism is why researchers sometimes informally refer to retatrutide's mechanism as "GLP-3" — though this is a colloquial shorthand rather than an official pharmacological designation, referencing the three receptor targets rather than a specific receptor subtype.

   For those asking "what is GLP-3?" in the context of obesity research, it refers to this triple-receptor approach. The term "GLP 3 peptide" or simply "GLP 3" has become popular shorthand in online communities discussing retatrutide triple hormone receptor agonist obesity treatment, even though the compound's formal classification is a tri-agonist rather than a GLP-3 receptor-specific agent.

Retatrutide research findings: weight, glucose, liver and heart markers

The trials summarised below measured body weight, glycemic markers, cardiovascular risk markers and liver fat in adults with obesity, overweight or type 2 diabetes. The figures are findings reported by those studies, not outcomes promised for any product.

Weight reduction in the phase 2 trial

In the phase 2 trial published in the New England Journal of Medicine, participants in the highest-dose group had a mean body weight reduction of 24.2% over 48 weeks. In the two highest-dose groups, every participant lost at least 5% of body weight, and 26% of the highest-dose group lost more than 30%.

Glycemic markers in type 2 diabetes

Studies published in The Lancet reported HbA1c reductions of up to 2.02% in participants with type 2 diabetes. The insulin-releasing effect of GLP-1 and GIP receptor activation is glucose-dependent, which is why the risk of hypoglycemia was described as low.

Cardiovascular risk markers

Clinical trial data showed reductions in systolic blood pressure and waist circumference and changes in lipid profiles (lower triglycerides, higher HDL cholesterol). These changes are consistent with the known effects of large weight reduction and GLP-1 receptor activation.

Hepatic fat and steatotic liver disease

The glucagon receptor component of retatrutide promotes hepatic fat oxidation, and clinical data reported large reductions in liver fat content among trial participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD). There are few pharmaceutical treatments for steatotic liver disease, which affects an estimated 25 to 30% of the global adult population.

Osteoarthritis and joint health

Joint outcomes were not a main endpoint in the retatrutide trials. Excess body weight is one of the strongest modifiable risk factors for knee and hip osteoarthritis, and research on weight reduction of 10% or more has reported improvements in joint pain, function and swelling. The retatrutide trials did not measure this.

Retatrutide Before and After — Clinical Trial Results

The retatrutide before and after data from published clinical trials paint a compelling picture of this peptide's effect. Rather than relying on anecdotal reports, the following section presents the actual retatrutide clinical trial results from peer-reviewed studies, providing the evidence base that has made retatrutide the most discussed investigational obesity compound in the world.

Phase 2 Trial: The Landmark NEJM Study (Jastreboff et al., 2023)

The pivotal Phase 2 trial, led by Dr. Ania Jastreboff and published in the New England Journal of Medicine, enrolled 338 adults with obesity (BMI =30) or overweight (BMI =27) with at least one weight-related comorbidity in a placebo-controlled setting. Participants were randomized to placebo or one of several retatrutide dose groups and followed for 48 weeks.

Results by group are shown below.

Table 2: Retatrutide Phase 2 Trial: Weight Loss Results by Trial Arm

In the highest-dose group, 26% of participants lost more than 30% of their body weight. The weight curves had not levelled off at the 48-week mark, so the trial did not establish where weight reduction would plateau.

Diabetes Population Results (The Lancet Studies)

Separate studies published in The Lancet assessed retatrutide mainly in populations with type 2 diabetes, where weight loss is often more hard to achieve due to the body effects of insulin resistance and diabetes drugs. Even in this more challenging population, retatrutide produced notable results: participants achieved about 16.9% body weight loss after 36 weeks, along with HbA1c reductions of up to 2.02%.

Phase 3 Trials: What to Expect

Eli Lilly has started Phase 3 clinical trials for retatrutide, which will enroll larger patient populations and run for longer durations to confirm the safety and effect saw in Phase 2. These trials are expected to assess retatrutide across multiple signs, including obesity, type 2 diabetes, and possibly steatotic liver disease and obstructive sleep apnea.

The retatrutide news from these Phase 3 trials will be key in finding the timeline for possible FDA approval and broader supply. Also, a retatrutide Parkinson's disease clinical trial has been announced, exploring whether the compound's brain-safe properties could benefit neurodegenerative conditions — a fascinating expansion of its possible treatment uses.

What the retatrutide trials measured

The phase 2 obesity trial (Jastreboff et al., 2023) was a 48-week, placebo-controlled study in 338 adults with obesity or overweight. Participants were randomized to placebo or one of several retatrutide dose groups, and the higher groups were reached by stepwise escalation, a design used to reduce gastrointestinal side effects. The trial measured percentage change in body weight and the share of participants reaching 5%, 10% and 15% weight reduction (Table 2 above). Weight reduction was larger in the higher-dose groups.

The phase 2 trial in type 2 diabetes (Rosenstock et al., 2023) ran for 36 weeks and measured HbA1c and body weight. The phase 3 TRIUMPH-1 trial measured body weight change at 80 weeks. For how the retatrutide and tirzepatide trial programs compare, see retatrutide vs tirzepatide. These are descriptions of study designs and measured outcomes; no regimen exists for research material.

Handling retatrutide in the lab

Retatrutide is supplied as a freeze-dried (lyophilized) powder and is dissolved in a suitable sterile diluent before laboratory use. Concentration is the peptide mass divided by the diluent volume: a 10 mg vial in 2 mL gives 5 mg/mL, and a 20 mg vial in 2 mL gives 10 mg/mL.

Dissolving and storing the peptide

1. 1
   Add the Diluent Slowly

   Swab the vial stopper with alcohol and add the diluent slowly down the inside wall of the vial rather than directly onto the powder. This limits foaming and peptide breakdown.

2. 2
   Mix Gently

   Once the diluent is added, gently swirl the vial in a circular motion until the powder is completely dissolved. Do not shake the vial vigorously — shaking can damage the peptide structure through mechanical stress. The solution should become clear with no visible particles. If cloudiness or particles remain, do not use the solution.

3. 3
   Store Properly

   Store the mixed retatrutide solution in a refrigerator at 2–8°C (36–46°F). Mixed peptide should be used within 28–30 days. Keep away from light and do not freeze the mixed solution. Freeze-dried (unreconstituted) peptide can be stored at -20°C for longer-term preservation.

Retatrutide vs Tirzepatide vs Semaglutide — Comparison Guide

One of the most often asked questions in the obesity pharmacotherapy space is how retatrutide vs tirzepatide and retatrutide vs semaglutide compare for effect, mechanism, and supply. The following head-to-head comparison provides a full overview of these three compounds.

Table 4: Retatrutide vs Tirzepatide vs Semaglutide — Head-to-Head Comparison

Retatrutide vs Tirzepatide: Key Differences

The retatrutide vs tirzepatide comparison is very relevant because both compounds are developed by Eli Lilly and share the GLP-1 and GIP receptor start mechanisms. The key difference is retatrutide's more glucagon receptor start, which adds a third body pathway focused on energy output and hepatic fat oxidation. In the Phase 2 trial, retatrutide achieved 24.2% mean weight loss vs.

tirzepatide's 22.5% in its Phase 3 SURMOUNT-1 trial — though direct head-to-head comparisons are complicated by differences in trial design, duration, and patient populations. The glucagon receptor component also gives retatrutide a possible advantage in liver fat reduction, which is an area where tirzepatide shows moderate but not dramatic effects.

Retatrutide vs Semaglutide: A Generational Leap

The retatrutide vs semaglutide comparison highlights the generational advancement that triple-agonist therapy represents. Semaglutide (Ozempic for diabetes, Wegovy for obesity) was considered a breakthrough when it achieved 15–17% mean weight loss in the STEP trials. Retatrutide's 24.2% result represents a 43–61% gain in weight loss effect over semaglutide — a difference that is clinically meaningful and not merely statistical.

The addition of GIP and glucagon receptor start provides mechanisms that semaglutide simply cannot access, explaining the large effect gap between these two generations of obesity pharmacotherapy.

Mazdutide vs Retatrutide

Another emerging comparison is mazdutide vs retatrutide. Mazdutide is a dual GLP-1/glucagon receptor agonist (without GIP start) developed by Innovent Biologics. While mazdutide has shown promising results in Chinese clinical trials, it lacks the GIP receptor component that adds to retatrutide's insulin potentiation and tolerability profile. The retatrutide vs mazdutide comparison illustrates how each more receptor target adds incrementally to the overall body effect, with retatrutide's triple mechanism providing the most full coverage of the three compounds.

Retatrutide Side Effects — What to Know Before You Buy

Grasp the possible side effects of retatrutide is essential for anyone considering this peptide for research or clinical evaluation. The safety profile saw in clinical trials is consistent with the known effects of GLP-1 receptor agonist class drugs, with gut effects being the most common category of adverse events.

Common Side Effects

Does Retatrutide Cause Hair Loss?

The question "does retatrutide cause hair loss" is one of the most common concerns raised by people researching this peptide. Hair loss was not identified as a common side effect in published retatrutide clinical trial data. However, rapid and major weight loss — regardless of the method — can trigger telogen effluvium, a temporary form of hair shedding caused by body stress.

This is a general consideration for any rapid weight loss intervention, not specific to retatrutide. People experiencing major weight loss may notice increased hair shedding, which often resolves as the body stabilizes at its new weight.

Retatrutide Side Effects Heart Considerations

About retatrutide side effects heart concerns, the clinical trial data actually showed favorable heart effects rather than adverse ones. Participants experienced reductions in systolic blood pressure, gains in lipid profiles, and reductions in waist circumference — all positive heart risk markers. A modest increase in heart rate was saw, consistent with the known class effect of GLP-1 receptor agonists, but this was not linked with adverse cardiac outcomes in the trial data.

Serious Adverse Events

Serious adverse events were rare in retatrutide clinical trials, aligning with the safety profiles often saw in the GLP-1 receptor agonist class. The overall safety profile was consistent with other GLP-1-based therapies, with no unexpected safety signals identified in Phase 2 data. Phase 3 trials will provide more full long-term safety data across larger and more diverse patient populations.

Retatrutide Cost, Price & Availability in 2026

Grasp retatrutide cost and current market pricing is essential for researchers and people assessing this peptide for investigational use. As an investigational compound not yet FDA-approved, retatrutide is available exclusively through research peptide suppliers rather than traditional pharmaceutical channels.

Current Retatrutide Price Breakdown

As of early 2026, the typical retatrutide price from reputable research peptide suppliers in the United States ranges as follows. Prices vary based on supplier, vial level, quantity bought, and current market conditions.

Table 5: Retatrutide Cost by Vial Size and Quantity

Is Retatrutide FDA Approved? Regulatory Status

As of early 2026, is retatrutide FDA approved? No. Retatrutide remains an investigational compound in Phase 3 clinical trials. It has not got FDA approval for any treatment sign. The FDA approval process needs successful completion of Phase 3 trials showing safety and effect in large patient populations, followed by a New Drug Use (NDA) review process that often takes 12–18 months.

Based on current trial timelines, possible FDA approval for retatrutide could occur in late 2026 or 2027, though this timeline is subject to change based on trial results and control review.

Retatrutide Prescription and Future Availability

Once FDA-approved, a retatrutide prescription would likely be available through endocrinologists, obesity medicine specialists, and main care physicians with appropriate training in body disease care. The prescription landscape for GLP-1-based therapies has expanded greatly in recent years.

Compounding pharmacy supply would depend on FDA regulations at the time of approval and the commercial supply of the branded product.

Where to Buy Retatrutide Peptide — Purchase Guide

Finding a reliable source to buy retatrutide peptide needs careful evaluation of suppliers, as the research peptide market varies greatly in quality, purity, and business practices. This section provides a full guide to navigating the retatrutide buy process safely and effectively.

How to Get Retatrutide: Current Purchasing Options

For those asking "retatrutide how to get" or "how to get retatrutide" in the current control environment, the main avenue is through specialized research peptide suppliers that operate legally in the United States. These suppliers sell retatrutide for research purposes only — not for human consumption or treatment use. The research peptide market is largely unregulated for product quality, which makes supplier selection critically important for getting pure, accurately dosed peptide.

What to Look for When Buying Retatrutide

1. 1
   Lot-Matched Certificates of Analysis (COA)

   The single most important quality indicator when you buy retatrutide online is a certificate of analysis that matches the lot number on your vial and can be verified. A COA should confirm the identity, purity, and amount of the peptide. PrymaLab tests every lot in its own laboratory (RP-HPLC purity, LC-MS identity), and its certificates can be checked at prymalab.net/testing/verify. Its third-party testing guarantee refunds the order and reimburses the test if any independent laboratory finds the wrong compound or less than the stated purity or amount.

   Always request and review the COA before buying.

2. 2
   HPLC Purity Verification

   High-performance liquid chromatography (HPLC) is the gold standard for peptide purity testing. Look for suppliers that provide HPLC purity results of =98% for their retatrutide products. HPLC testing confirms that the peptide is the correct compound and that impurities are within acceptable limits. Mass spectrometry (MS) confirmation of cell-level weight is an more quality indicator that the best suppliers provide.

3. 3
   Transparent Business Practices

   Trustworthy suppliers for retatrutide peptide buy USA buys keep transparent business practices, including clear contact data, responsive customer service, detailed product descriptions, and honest representation of their products as research chemicals. Avoid suppliers that make treatment claims, promise specific health outcomes, or operate without clear business finding.

4. 4
   Customer Reviews and Reputation

   Before placing a retatrutide peptide order, research the supplier's reputation through independent review platforms, research community forums, and verified customer testimonials. Long-set up suppliers with consistent positive reviews and active community presence are often more reliable than newer or anonymous vendors. Look for specific mentions of product quality, accurate fill amounts, and responsive customer service.

5. 5
   Proper Storage and Shipping

   Peptides are sensitive to heat and moisture. Reputable suppliers ship freeze-dried peptides with appropriate cold-chain packaging, including ice packs or dry ice for heat-sensitive shipments. Verify that the supplier uses proper packaging materials and offers expedited shipping options to minimize transit time and heat exposure. Freeze-dried peptide is more stable than mixed peptide during shipping.

Where to Buy Retatrutide Online in the USA

When searching for where to buy retatrutide or "retatrutide buy online USA," focus on set up research peptide companies that have been operating for multiple years, keep transparent quality records, and have verifiable positive reputations in the research community. PrymaLab offers research-grade retatrutide with every lot tested in its own laboratory (RP-HPLC purity, LC-MS identity), certificates that can be checked against the lot number at prymalab.net/testing/verify, and customer support for researchers.

For those searching for retatrutide for sale online, retatrutide peptide buy online, or where to buy peptides for weight loss research, the key principle is to prioritize quality check over price. The cheapest option is rarely the best option when it comes to research peptides, where purity and accurate level are essential for meaningful research outcomes.

Frequently Asked Questions About Retatrutide

Related reading

• Cagrilintide and CagriSema: mechanism, trial data and safety
• Tesofensine: trials, half-life and approval status

References & Further Reading

The following peer-reviewed sources were used in the preparation of this article. All citations link to their original publications.

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
2. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: a Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA. The Lancet. 2023;402(10401):529–544. doi:10.1016/S0140-6736(23)01053-X
3. Coskun T, Urva S, Roell WC, et al. LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist for Glycemic Control and Weight Loss: From Discovery to Clinical Proof of Concept. Cell Metabolism. 2022;34(9):1234–1247. doi:10.1016/j.cmet.2022.08.003
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
6. Finan B, Yang B, Ottaway N, et al. A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents. Nature Medicine. 2015;21(1):27–36. doi:10.1038/nm.3761
7. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
8. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatohepatitis: A Randomized Phase 2a Trial. Nature Medicine. 2024;30(8):2037–2048. doi:10.1038/s41591-024-03018-2
9. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-Obesity Drug Discovery: Advances and Challenges. Nature Reviews Drug Discovery. 2022;21(3):201–223. doi:10.1038/s41573-021-00337-8
10. Eli Lilly and Company. Lilly's Retatrutide (LY3437943) Achieved Up to 24.2% Body Weight Reduction at 48 Weeks in Adults with Obesity or Overweight in Phase 2 Study. Press Release. June 2023. Available at: investor.lilly.com